Skip to content

Comparative Evaluation of Dexmedetomidine, Ketamine and Magnesium Sulphate for treatment of Perioperative Shivering after Spinal Anaesthesia

Comparison of Dexmedetomidine, Ketamine and Magnesium Sulphate for treatment of Perioperative Shivering after Spinal Anaesthesia - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/108570
Enrollment
120
Registered
2026-04-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: DEXMEDETOMIDINE IV: Inj DEXMEDETOMIDINE 0.5 MCG/KG IV over 10 minutes Intervention2: KETAMINE IV: Inj KETAMINE 0.5 MG/KG IV bolus Intervention3: MAGNESIUM SULPHATE IV: Inj MAGNESIUM SUL

Sponsors

JSS Academy Of Higher Education And Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of age 18 to 60 years of ASA grade 1, 2 and 3 undergoing elective surgery under spinal anaesthesia with grade 2 and above shivering

Exclusion criteria

Exclusion criteria: 1. Patients with ASA physical status above 3. 2. Patients allergic or contraindicated to study medication. 3. Patients with severe cardio pulmonary disease, renal or liver impairment, peri operative fever or hypothermia, history of seizure, massive blood transfusion and history of psychiatric illness.

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of Dexmedetomidine, Ketamine, Magnesium Sulphate in the treatment of peri operative shivering subsequent to spinal AnesthesiaTimepoint: After study drug administration shivering grade will be assessed at 1, 3, 5 minutes and thereafter every 5 minutes till shivering resolves or 30 minutes has elapsed.

Secondary

MeasureTime frame
1. To assess the hemodynamic parameters after giving the study drugs. 2. To compare side effects of the drugs including nausea, vomiting, hypotension, hypertension, bradycardia, tachycardia, sedation, respiratory depression, delirium, hypothermia.Timepoint: After administration of the study drug all secondary outcomes will be assessed at 1, 3, 5 minutes & thereafter every 5 minutes till 30 minutes.

Countries

India

Contacts

Public ContactDr Archana K N

JSS Academy Of Higher Education And Reasearch

devamdev@yahoo.com7069010268

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026